The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility

Cell

Volumn 111, Issue 2, 2002, Pages 209-218

  Liu, Yichin ^a   Fallon, Lara ^a   Lashuel, Hilal A ^a   Liu, Zhihua ^a   Lansbury, Peter T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BRAIN ENZYME; HYDROLASE; LIGASE; MUTANT PROTEIN; PROTEASOME; UBIQUITIN C TERMINAL HYDROLASE 1; UBIQUITYL LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; DIMERIZATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME ACTIVITY; GENETIC CODE; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; WILD TYPE;

EID: 0037131567     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(02)01012-7     Document Type: Article

References (47)

1. Bence N.F., Sampat R.M., Kopito R.R. Impariment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
2. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274:1999;33855-33858.
3. Chain D.G., Hegde A.N., Yamamoto N., Liu-Marsh B., Schwartz J.H. Persistent activation of cAMP-dependent protein kinase by regulated proteolysis suggests a neuron-specific function of the ubiquitin system in Aplysia. J. Neurosci. 15:1995;7592-7603.
4. Ciechanover A., Hod Y., Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem. Biophys. Res. Commun. 81:1978;1100-1105.
5. Cole R.N., Hart G.W. Cytosolic O-glycosylation is abundant in nerve terminals. J. Neurochem. 79:2001;1080-1089.
6. Conway K.A., Rochet J.-C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science. 294:2001;1346-1349.
7. Dang L.C., Melandri F.D., Stein R.L. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry. 37:1998;1868-1879.
8. Engelender T.Y., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A.L., Dawson V., Dawson T.M., Ross C.A. Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10:2001;919-926.
9. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 268:1995;726-731.
10. Fernandez-Funez P., Nino-Rosales M.L., de Gouyon B., She W.C., Luchak J.M., Martinez P., Turiegano E., Benito J., Capovilla M., Skinner P.J.et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 408:2000;101-106.
11. Hell J.W., Jahn R. Bioenergetic characterization of gamma-aminobutyric acid transporter of synaptic vesicles. Methods Enzymol. 296:1998;116-124.
12. Hofmann R.M., Pickart C.M. In vitro assembly and recognition of Lys-63 polyubiquitin chains. J. Biol. Chem. 276:2001;27936-27943.
13. Johnston S.C., Larsen C.N., Cook W.J., Wilkinson K.D., Hill C.P. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 Å resolution. EMBO J. 16:1997;3787-3796.
14. Johnston S.C., Riddle S.M., Cohen R.E., Hill C.P. Structural basis for the specificity of ubiquitin C-terminal hydrolases. EMBO J. 18:1999;3877-3887.
15. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
16. Kurihara L.J., Kikuchi T., Wada K., Tilghman S.M. Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia. Hum. Mol. Genet. 10:2001;1963-1970.
17. Lam Y.A., Pickart C.M., Alban A., Landon M., Jamieson C., Ramage R., Mayer R.J., Layfield R. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:2000;9902-9906.
18. Lansbury P.T. Jr., Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Genet. Dev. 12:2002;299-306.
19. Larsen C.N., Price J.S., Wilkinson K.D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases. identification of two active site residues Biochemistry. 35:1996;6735-6744.
20. Larsen C.N., Krantz B.A., Wilkinson K.D. Substrate specificity of deubiquitinating enzymes. ubiquitin C-terminal hydrolases Biochemistry. 37:1998;3358-3368.
21. Layfield R., Alban A., Mayer R.J., Lowe J. The ubiquitin protein catabolic disorders. Neuropathol. Appl. Neurobiol. 27:2001;171-179.
22. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T.et al. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
23. Levecque C., Destee A., Mouroux V., Becquet E., Defebvre L., Amouyel P., Chartier-Harlin M.C. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J. Neural Transm. 108:2001;979-984.
24. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 53:1999;1858-1860.
25. Mastrandrea L.D., You J., Niles E.G., Pickart C.M. E2/E3-mediated assembly of lysine 29-linked polyubiquitin chains. J. Biol. Chem. 274:1999;27299-27306.
26. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:2001;589-594.
27. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 13:2002;1437-1441. a.
28. McNaught K.S., Mytilineou C., JnoBaptiste R., Yabut J., Shashidharan P., Jenner P., Olanow C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81:2002;301-306. b.
29. Miura H., Oda K., Endo C., Yamazaki K., Shibasaki H., Kikuchi T. Progressive degeneration of motor nerve terminals in GAD mutant mouse with hereditary sensory axonopathy. Neuropathol. Appl. Neurobiol. 19:1993;41-51.
30. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 51:2002;133-136.
31. Moraes T.F., Edwards R.A., McKenna S., Pastushok L., Xiao W., Glover J.N., Ellison M.J. Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13. Nat. Struct. Biol. 8:2001;669-673.
32. Mukoyama M., Yamazaki K., Kikuchi T., Tomita T. Neuropathology of gracile axonal dystrophy (GAD) mouse. An animal model of central distal axonopathy in primary sensory neurons. Acta Neuropathol. 79:1989;294-299.
33. Naze P., Vuillaume I., Destee A., Pasquier F., Sablonniere B. Mutation analysis and association studies of ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci. Lett. 328:2002;1-4.
34. Oda K., Yamazaki K., Miura H., Shibasaki H., Kikuchi T. Dying back type axonal degeneration of sensory nerve terminals in muscle spindles of the gracile axonal dystrophy (GAD) mutant mouse. Neuropathol. Appl. Neurobiol. 18:1992;265-281.
35. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:2001;503-533.
36. Rideout H.J., Larsen K.E., Sulzer D., Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78:2001;899-908.
37. Rochet J.C., Lansbury P.T. Jr. Amyloid fibrillogenesis. themes and variations Curr. Opin. Struct. Biol. 10:2000;60-68.
38. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T., Wada K. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23:1999;47-51.
39. Satoh J., Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 189:2001;113-117.
40. Shtilerman M.D., Ding T.T., Lansbury P.T. Jr. Molecular crowding accelerates fibrillization of alpha-synuclein. could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry. 41:2002;3855-3860.
41. Stafford W.F. 3rd. Boundary analysis in sedimentation transport experiments. a procedure for obtaining sedimentation coefficient distributions using the time derivative of the concentration profile Anal. Biochem. 203:1992;295-301.
42. Tofaris G.K., Layfield R., Spillantini M.G. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509:2001;22-26.
43. VanDemark A.P., Hofmann R.M., Tsui C., Pickart C.M., Wolberger C. Molecular insights into polyubiquitin chain assembly. crystal structure of the Mms2/Ubc13 heterodimer Cell. 105:2001;711-720.
44. Wang J., Zhao C.-Y., Si Y.-M., Liu Z.-L., Chen B., Yu L. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov. Disord. 17:2002;767-771.
45. Weissman A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2:2001;169-178.
46. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 246:1989;670-673.
47. Wu J., Ichihara N., Chui D.H., Yamazaki K., Kikuchi T. Ubiquitin immunoreactivity in the central nervous system of gracile axonal dystrophy (GAD) mouse. No To Shinkei. 47:1995;881-885.